Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-03
2006-10-03
Shameem, Golam M. M. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253050, C514S253060, C514S253130, C514S254090, C544S359000, C544S363000, C544S365000, C544S373000, C544S376000, C544S379000
Reexamination Certificate
active
07115607
ABSTRACT:
Selected substituted piperazine compounds of Formula Iare effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
REFERENCES:
patent: 5244895 (1993-09-01), Hidaka et al.
patent: 5340809 (1994-08-01), Gaudry et al.
patent: 5518735 (1996-05-01), Sturzebecher et al.
patent: 5576290 (1996-11-01), Hadley
patent: 5681954 (1997-10-01), Yamamoto et al.
patent: 5721251 (1998-02-01), Chen et al.
patent: 6051555 (2000-04-01), Hadley
patent: 6054556 (2000-04-01), Huby et al.
patent: 6057290 (2000-05-01), Fukiage et al.
patent: 6767915 (2004-07-01), Bakshi et al.
patent: 2002/0091090 (2002-07-01), Cole et al.
patent: 2004/0006067 (2004-01-01), Fotsch et al.
patent: 0 513 691 (1996-07-01), None
patent: 1 086 947 (2001-03-01), None
patent: WO 94/05693 (1994-03-01), None
patent: WO 95/34311 (1995-12-01), None
patent: WO 97/03060 (1997-01-01), None
patent: WO 97/19908 (1997-06-01), None
patent: WO 97/19919 (1997-06-01), None
patent: WO 97/40031 (1997-10-01), None
patent: WO 97/49673 (1997-12-01), None
patent: WO 98/11128 (1998-03-01), None
patent: 99/11657 (1999-03-01), None
patent: WO 96/64002 (1999-12-01), None
patent: WO 00/25786 (2000-05-01), None
patent: WO 00/35874 (2000-06-01), None
patent: WO 00/35875 (2000-06-01), None
patent: 01/34586 (2000-11-01), None
patent: WO 00/74679 (2000-12-01), None
patent: WO 00/78317 (2000-12-01), None
patent: WO 01/10842 (2001-02-01), None
patent: WO 02/059095 (2002-08-01), None
patent: WO 02/059107 (2002-08-01), None
patent: WO 02/059108 (2002-08-01), None
patent: WO 02/059117 (2002-08-01), None
patent: WO 02/062766 (2002-08-01), None
patent: WO 02/067869 (2002-09-01), None
patent: WO 02/068387 (2002-09-01), None
patent: WO 02/068388 (2002-09-01), None
patent: WO 02/069905 (2002-09-01), None
patent: WO 02/070511 (2002-09-01), None
patent: WO 02/079146 (2002-10-01), None
patent: WO 03/031410 (2003-04-01), None
patent: WO 03/061660 (2003-07-01), None
patent: WO 03/063781 (2003-08-01), None
Andersson et al. Expert Opin. Ther.Patents, vol. 11, p. 1583-1592 (2001).
Bohm et al., “Three Dimensional Quantitative Structure—Activity Relationship Analyses Using Comparative Molecular Field Analysis and comparative Molecular Similarity Indices Analysis to Elucidate Selectivity Differences of Inhibitors Binding to Trypsin, Thrombin, and Factor Xa” (1999) J. Med. Chem. 42: 458-477.
Hadley et al., “Melanocortin Receptors: Identification and Characterization by Melanotropic Peptide Agonists and Antagonists” (1996) Pigment Cell Research 9: 213-234.
Haskell-Luevano et al., “Discovery of Prototype Peptidomimetic Agonists at the Human Melanocortin Receptors MC1R and MC4R” (1997) J. Med. Chem., 40: 2133-2139.
Jacobsen et al., “Synthesis of a Series of Stromelysin-Selective Thiadiazole Urea Matrix Metalloproteinase Inhibitors” (1999) J. Med. Chem., 42: 1525-1536.
Sakamoto et al., “Chymotrypsin Inhibition by Dipeptide Esters, Phenylpiperidide and Phenylpiperazides” (1989) Peptide Chemistry 375-378.
Sakamoto et al., “Dipeptide Side Chain-Side chain Hydrophobic Interactions as Conformational Core for Chymotrypsin Inhibition” (1991) Bull. Chem. Soc. Jpn., 64: 2519-2523.
Schioth et al., (1998) “Discovery of Novel Melanocortin4Receptor Selective MSH Analogues” British Journal of Pharmacology 124: 75-82.
Sturzebecher et al., “Structure-Activity Relationships of Inhibitors Derived From 3-Amidinophenylalanine” (1995) J. Enzyme Inhibition, 9:87-99.
Sturzebecher et al., “Synthesis and Structure—Activity Relationships of Potent Thrombin Inhibitors: Piperazides of 3-Amidinophenylalanine” (1997) J. Med. Chem. 40: 3091-3099.
Wagner et al., “Synthese antiproteolytisch wirksame N -arylsulfonylierter Amidinophenylalaninamide” (1981) Pharmazie 36: 597-603.
Wikberg, Jarl E.S., “Melanocortin receptors: perspectives for novel drugs” (1999) European Journal of Pharmacology 375: 295-310.
Barakat et al., “Synthesis and Biological Activities of Phenyl Piperazine-Based Peptidomimetic Growth Hormone Secretagogues” (1998) Bioorganic & Medicinal Chemistry Letters 8: 1431-1436.
Arasasingham Premilla
Bo Yunxin
Chen Ning
Fotsch Christopher H.
Goldberg Martin H.
Amgen Inc.
Bulock Joseph W.
LandOfFree
Substituted piperazinyl amides and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted piperazinyl amides and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted piperazinyl amides and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3694748